1. Short title This Act may be cited as Aidan’s Law . 2. Findings Congress finds the following: (1) Adrenoleukodystrophy is a deadly genetic disease that destroys myelin, the protective sheath that surrounds the brain’s neurons, which are the nerve cells that allow us to think and to control our muscles. (2) Adrenoleukodystrophy affects 1 in 17,000 people and most severely affects boys and men. (3) Adrenoleukodystrophy newborn screening tests have been validated with false positive of less than 0.1 percent. (4) Early identification of adrenoleukodystrophy allows those who are affected to be treated and have the best chance at a healthy life. 3. Screening of adrenoleukodystrophy (a) In general Part A of title XI of the Public Health Services Act ( 42 U.S.C. 300b–1 et seq.) is amended by adding at the end the following: 1118. Adrenoleukodystrophy (a) In general Each hospital, child care center, clinic, or other similar institution caring for infants who are 28 days or less of age (as designated by the Secretary) may administer, or cause to have administered, to every such infant in its care a test for adrenoleukodystrophy in accordance with this section. (b) Process (1) In general In carrying out this section, the chief executive officer for health in each State may prescribe standards and procedures for the administration of testing under subsection (a), including recording the results of such tests, tracking activities, conducting follow-up reviews, and carrying out educational activities. (2) Dissemination of information In carrying out this section, the chief executive officer for health in each State may prescribe standards and procedures setting forth the manner in which testing information is disseminated to a parent or guardian of the infant to be tested. (3) Failure to prescribe If a State has not prescribed standards and procedures that are approved as provided for in paragraph (4) by the date that is 2 years after the date of enactment of this section, the Discretionary Advisory Committee on Heritable